2022 World Conference on Lung Cancer (ePosters)-EP08.01-008. Immune Checkpoint Inhibitors in Oncogenic Driven Non-small Cell Lung Cancer

Pdf Summary

In this study, the efficacy of immune checkpoint inhibitors (ICIs) in patients with oncogenic driven non-small cell lung cancer (NSCLC) was analyzed. The majority of patients receiving ICI monotherapy had at least one mutation, while a minority of patients with target mutations received ICI. The presence of mutations did not significantly affect the overall survival (OS) and progression-free survival (PFS) in patients receiving ICI as first-line treatment. However, the limited number of patients with certain oncogenic alterations made it difficult to draw firm conclusions. <br /><br />The study included 131 patients with advanced NSCLC who received ICI monotherapy. The mean age of the patients was 64 years. The most common histology type was adenocarcinoma, followed by squamous carcinoma and poorly differentiated NSCLC. Among the mutated genes, KRAS was the most common, followed by BRAF, MET, EGFR, HER2, RET, ALK, PDGFRA, and others. A total of 95 mutations were identified in the patients.<br /><br />ICI was administered as first-line treatment in 84 patients, while 47 patients received ICI as subsequent lines of treatment. Only 8.4% of patients had mutations that were eligible for targeted therapy (EGFR and ALK), and these patients received ICI as subsequent line treatment. Out of the patients included in the study, 81 had one mutation and 50 had no mutations.<br /><br />The findings of this study suggest that the efficacy of ICIs in oncogenic driven NSCLC may vary depending on the mutation status. Non-mutated NSCLC patients had superior OS and PFS when receiving ICI as first-line treatment. However, due to the limited number of patients with certain mutations, further studies are needed to analyze the efficacy of ICIs in each mutation separately and as different lines of treatment. Overall, the study highlights the importance of considering the molecular tumor profile when determining the appropriate treatment approach for NSCLC patients.

Asset Subtitle

Ana Fonseca

Meta Tag

Speaker Ana Fonseca

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

immune checkpoint inhibitors

oncogenic driven non-small cell lung cancer

ICI monotherapy

mutation

overall survival

progression-free survival

advanced NSCLC

histology type

mutated genes

targeted therapy